Vimarsana.com

Latest Breaking News On - Biogen international - Page 4 : vimarsana.com

Australia: Achieving early generic/biosimilar market entry

New developments in Australia’s Patent Office and its courts have confirmed that overturning a patent term extension may be the “sleeper” strategy to achieve early generic/biosimilar market entry in Australia.

Australia
Switzerland
Australian
Dohmev-sandoz
Biogen-internationalv-pharmacor
Patent-office
Australian-register
Therapeutic-goods
Ono-pharmaceutical
Merck-sharp
Federal-court
Biogen-international

Federal Circuit Denies En Banc Review of Patent Written Description

Federal Circuit denied a patent owner’s request for en banc rehearing of a panel decision that invalidated a patent for lack of written description. Biogen International GMBH, Biogen MA, Inc. v. Mylan Pharmaceuticals Inc.

Biogen-ma-inc
Biogen-international
Us-court
Mylan-pharmaceuticals-inc
Federal-circuit
Pharmaceuticals-inc
Chief-judge-moore
Judge-newman
Legal
Usiness
Federal-circuit

vimarsana © 2020. All Rights Reserved.